Pricing Log in Create free account
Saturday 17 October 2026 Export MGTX’s income statement to Excel — free account

MeiraGTx Holdings PLC

MGTX Healthcare Biotechnology

MeiraGTx Holdings PLC’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 144.6% from fiscal 2024. In the quarter to June 2026, revenue grew 8,608.6%, EPS grew 466.7%, free cash flow grew 13.1% and total debt rose 28.6%, each against the same quarter a year earlier.

9.28 0.61 −6.17%
Market cap
$949.9M
P/E
12.2×
Fwd P/E
−5.6×
Dividend yield
—
F-score
5/9
Altman Z
−4.39
Beneish M
−3.01
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

MeiraGTx Holdings PLC (MGTX) Business Profile

Updated before January 2025

Company Overview

MeiraGTx Holdings PLC (NASDAQ: MGTX) is a clinical-stage gene therapy company focused on developing transformative treatments for patients suffering from severe diseases. Founded in 2015, the company is headquartered in London, United Kingdom, with additional operations in New York, USA, and Shannon, Ireland. MeiraGTx was established with the vision of leveraging cutting-edge gene therapy technologies to address unmet medical needs across various therapeutic areas. The company is led by a team of seasoned professionals, including CEO Alexandria Forbes, Ph.D., who brings extensive experience in biotechnology and pharmaceutical development.

Core Business Segments

MeiraGTx operates across several core business segments, each focused on advancing gene therapy solutions:

1. Gene Therapy Programs

MeiraGTx develops gene therapy treatments targeting a range of diseases, including:

  • Ophthalmology: The company is advancing therapies for inherited retinal diseases (IRDs) such as X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM).
  • Neurology: MeiraGTx is working on treatments for neurodegenerative diseases, including Parkinson’s disease.
  • Other Rare Diseases: The company is exploring gene therapies for conditions such as xerostomia, a severe dry mouth condition often caused by radiation therapy in cancer patients.

2. Proprietary Gene Therapy Platform

MeiraGTx has developed a proprietary gene therapy platform that integrates:

  • Vector Design and Manufacturing: The company designs and produces viral vectors used to deliver therapeutic genes to target cells.
  • Promoter Technology: MeiraGTx utilizes advanced promoter systems to ensure precise and efficient gene expression.
  • Regulatory Elements: The platform includes regulatory elements that enhance the safety and efficacy of gene therapies.

3. Manufacturing and Supply Chain

MeiraGTx owns and operates a state-of-the-art manufacturing facility in Shannon, Ireland. This facility enables the company to maintain control over the production process, ensuring high-quality and scalable manufacturing of gene therapy products.

Business Model

MeiraGTx’s business model is centered on the integration of research, development, and manufacturing to deliver innovative gene therapy solutions. The company generates revenue through:

  • Collaborations and Partnerships: MeiraGTx has established strategic partnerships with leading pharmaceutical companies, such as Janssen Pharmaceuticals, to co-develop and commercialize gene therapy products.
  • Licensing Agreements: The company licenses its proprietary technologies and intellectual property to other organizations.
  • Clinical Development Milestones: MeiraGTx receives payments tied to the achievement of clinical and regulatory milestones.

By maintaining in-house manufacturing capabilities and leveraging its proprietary platform, MeiraGTx ensures a streamlined and cost-effective approach to bringing therapies to market.

Strategic Direction

MeiraGTx is committed to advancing its pipeline of gene therapy candidates and expanding its technological capabilities. Key strategic priorities include:

  • Pipeline Expansion: The company aims to broaden its portfolio by targeting additional therapeutic areas, including oncology and metabolic disorders.
  • Global Reach: MeiraGTx plans to expand its presence in key markets, including North America, Europe, and Asia.
  • Sustainability Goals: The company is focused on minimizing its environmental footprint by adopting sustainable manufacturing practices and reducing waste.
  • Innovation: MeiraGTx continues to invest in research and development to enhance its gene therapy platform and explore novel delivery systems.

Competitive Landscape

MeiraGTx operates in a highly competitive gene therapy market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Spark Therapeutics (a subsidiary of Roche): Known for its FDA-approved gene therapy, Luxturna, for retinal diseases.
  • Bluebird Bio: Focused on gene therapies for severe genetic diseases and cancer.
  • Sarepta Therapeutics: Specializes in genetic medicine for rare diseases, including Duchenne muscular dystrophy.
  • uniQure: Develops gene therapies for hemophilia and other rare conditions.

Despite the competition, MeiraGTx differentiates itself through its integrated platform, in-house manufacturing capabilities, and focus on precision medicine.

Risk Factors

Like any biotech company, MeiraGTx faces several risks, including:

  • Regulatory Challenges: The approval process for gene therapies is complex and subject to stringent regulatory scrutiny.
  • Market Dependence: The company’s success is heavily reliant on the commercial viability of its pipeline products.
  • Supply Chain Disruptions: Any issues in the supply chain could impact the production and delivery of therapies.
  • Financial Risks: As a clinical-stage company, MeiraGTx depends on external funding and may face financial constraints if it fails to secure additional capital.

Recent Developments

MeiraGTx has made significant progress in advancing its pipeline and strengthening its operational capabilities:

  • Clinical Trials: The company has reported positive interim data from its Phase 1/2 clinical trials for XLRP and ACHM gene therapies.
  • Partnerships: MeiraGTx expanded its collaboration with Janssen Pharmaceuticals to include additional therapeutic areas.
  • Manufacturing Expansion: The company completed the expansion of its Shannon facility to support commercial-scale production.
  • Global Developments: The COVID-19 pandemic posed challenges but also highlighted the importance of innovative therapies, driving increased interest in gene therapy solutions.

Investment Considerations

Investors considering MeiraGTx should weigh the following factors:

Strengths:

  • Innovative Platform: Proprietary technologies and in-house manufacturing capabilities.
  • Strong Pipeline: Promising gene therapy candidates targeting high-value markets.
  • Strategic Partnerships: Collaborations with industry leaders like Janssen Pharmaceuticals.

Risks:

  • Clinical and Regulatory Uncertainty: The success of the pipeline depends on clinical trial outcomes and regulatory approvals.
  • Financial Dependence: The company may require additional funding to sustain operations.
  • Market Competition: Intense competition from other gene therapy developers.

Conclusion

MeiraGTx Holdings PLC is a pioneering company in the gene therapy space, with a robust pipeline, innovative platform, and strategic partnerships. While the company faces challenges typical of the biotech industry, its integrated approach and focus on precision medicine position it for long-term growth. As the demand for gene therapies continues to rise, MeiraGTx is well-positioned to capitalize on emerging opportunities and deliver transformative treatments to patients worldwide.